Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

c-KIT signaling as the driving oncogenic event in sub-groups of melanomas.

Histology and histopathology - 1 May 2009

Smalley Keiran S M, Sondak Vernon K, Weber Jeffrey S

Abstract excerpt

As we enter the era of targeted therapy for melanoma, attempts are being made to sub-group tumors on the basis of their driving oncogenic mutations, with the hope of developing truly personalized therapeutic regimens. c-KIT is a receptor tyrosine kinase whose aberrant activation is implicated in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Imatinib Mesylate
Share to Melanocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma, Experimental

Share to Piperazines

Share to Proto-Oncogene Proteins c-kit

Share to Stem Cell Factor

Share to Uveal Neoplasms

Source

Identifiers

PMID: 19283671
DOI: 10.14670/HH-24.643

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19283671-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

c-KIT signaling as the driving oncogenic event in sub-groups of melanomas.PMID 19283671Read ↗

KIT and Melanoma: Biological Insights and Clinical Implications.Semantic proximity Read ↗

Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics.Semantic proximity Read ↗

c-Kit mutants require hypoxia-inducible factor 1alpha to transform melanocytes.Semantic proximity Read ↗

C-kit-mutated melanomas: the Chinese experience.Semantic proximity Read ↗

Advances in targeted therapy for melanoma.Semantic proximity Read ↗

MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanomaSemantic proximity Read ↗

Pharmacological inhibitors of c-KIT block mutant c-KIT mediated migration of melanocytes and melanoma cells in vitro and in vivo.Semantic proximity Read ↗

KIT as a therapeutic target in metastatic melanoma.Semantic proximity Read ↗

Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.Semantic proximity Read ↗

Mucosal melanomas of the head and neck: new aspects of the clinical outcome, molecular pathology, and treatment with c-kit inhibitors.Semantic proximity Read ↗

KIT mutations in a series of melanomas and their impact on treatment with imatinib.Semantic proximity Read ↗

Clinical and genomic correlates of imatinib response in melanomas with KIT alterations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.